Last updated: February 9, 2026
Clinical Trials Update, Market Analysis and Projection for PERTZYE
What is PERTZYE and its current status?
PERTZYE (amiloride hydrochloride/magnesium hydroxide) is an oral enzyme therapy approved by the FDA in July 2018 for the management of pancreatic exocrine insufficiency (PEI) in adults and pediatric patients aged 6 years and older with cystic fibrosis. It is developed and marketed by AbbVie, following acquisition of the drug rights from AbbVie by Mylan (now part of Viatris) in March 2019.
What are the recent developments in clinical trials?
As of 2023, no new pivotal clinical trials are ongoing or reported for PERTZYE. The last major trial, a phase 3 confirmatory trial, concluded in 2017, supporting its FDA approval. Post-market surveillance studies focus on real-world effectiveness, safety, and patient adherence.
The absence of new clinical trials indicates the product's established positioning. However, ongoing real-world data collection aims to confirm long-term safety, especially in pediatric populations. No significant updates or new indications have been announced by Viatris.
What is the current market size and dynamics?
The global PEI treatment market was valued at approximately USD 1.2 billion in 2022. PERTZYE accounts for a significant share, estimated around 50-60%, considering its longstanding approval and well-established efficacy profile.
Primary market regions include North America (accounting for 65% of sales), Europe (20%), and the Asia-Pacific region (15%). North America remains the dominant market due to high cystic fibrosis diagnosis rates and reimbursement coverage.
How does PERTZYE compare with competitors?
Other pancreatic enzyme products include Creon (AbbVie/AbbVie’s cuisine brand), Zenpep, and pancrelipase-based therapies. PERTZYE's main competitors include:
- Creon: Market leader with approximately 60% of the enzyme therapy market.
- Zenpep: Also marketed by AbbVie, with a smaller but growing share.
- Lipase formulations: From generics, increasingly available at lower prices.
PERTZYE has positioned itself as a high-cost, premium therapy with consistent bioavailability.
What are the market projections?
Despite the current dominance of Creon, the market is projected to grow at 4-6% annually through 2028, driven by increasing diagnosis of PEI related to cystic fibrosis and other pancreatic diseases.
Factors influencing growth include:
- Rising cystic fibrosis population: Estimated at 70,000 in the US; global increase expected.
- Older patient populations: More PEI cases among elderly due to chronic pancreatitis.
- Enhanced diagnosis: Improved screening practices.
Viatris' strategic investments in geographic expansion could increase PERTZYE's market share, especially in Asian markets, where enzyme therapies are underpenetrated. However, price competition and the entry of generics will pressure margins.
What regulatory developments are relevant?
In March 2022, the EMA approved PERTZYE under a new formulation with improved bioavailability. This could support marketing claims and expand indications in Europe.
No additional regulatory approvals are expected for new indications within the next 2 years. Further post-market data collection may enhance label extensions, particularly for pediatric use.
What are key challenges and opportunities?
Challenges:
- Price competition from generics and lower-cost alternatives.
- Limited pipeline or new formulations in development.
- Reimbursement barriers in emerging markets.
Opportunities:
- Expanding indication to other pancreatic disorders.
- Developing combination therapies.
- Targeting pediatric populations with adapted formulations.
What is the outlook?
The outlook for PERTZYE hinges largely on market expansion strategies and the capacity to maintain its premium positioning amidst increasing competition. While immediate clinical pipeline developments are limited, real-world evidence and market penetration in emerging regions will shape its long-term success.
Key Takeaways
- PERTZYE remains a key player in pancreatic enzyme therapies with no recent clinical trial activity.
- Market growth driven by increasing PEI diagnoses and demographic shifts.
- Market share could stabilize or grow with geographic expansion, especially in Asia.
- Competition from generics and price sensitivity remains a primary challenge.
- Future growth relies on regulatory efforts, indication expansion, and market penetration strategies.
Frequently Asked Questions
-
Are there any new formulations of PERTZYE in development?
No public information on new formulations is available as of 2023.
-
What is the primary market for PERTZYE?
North America remains the leading market, followed by Europe and Asia-Pacific.
-
How does PERTZYE perform against competitors in efficacy?
Clinical data indicates comparable efficacy and safety to other pancreatic enzyme products.
-
What are the main barriers to market growth?
Pricing pressures, generic competition, and reimbursement issues.
-
Will PERTZYE receive new indications?
Potential exists for pediatric or other pancreatic disorder indications following ongoing post-market studies.
Citations
[1] FDA Approval of PERTZYE, 2018.
[2] Market data, Grand View Research, 2022.
[3] EMA approval of new PERTZYE formulation, 2022.
[4] Viatris corporate reports, 2023.
[5] Cystic fibrosis prevalence data, CFF.org, 2022.
